1.Experimental study on inhibitory effect of glycyrrhizin on HSV-1 in vitro
Journal of Chongqing Medical University 1986;0(02):-
Objective:To investigate the inhibitory effect of glycyrrhizin on HSV-1 in vitro,and to search a new drug against herpes simplex encephalitis.Methods:The Vero cells were cultured and divided into three groups:the group treated with glycyrrhizin after absorption of HSV-1 into the Vero cells,the group of pretreated cells and the group of pretreated HSV-1 with both glycyrrhizin before absorption of HSV-1 into the Vero cells.The plaque formation units were observed to evaluate the inhibitory effect of glycyrrhizin on HSV-1 and the stage when the virus replicating was inhibited.Results:Glycyrrhizin treatment after the absorption of virus into the cells obviously reduced the plaque formation units due to the virus infection and IC 50 was 0.56mM.Pretreated cells and pretreated HSV-1 with glycyrrhizin before absorption of HSV-1 into the cells did not reduce the plaque formation units.Conclusion:Glycyrrhizin can markedly inhibit the replication of HSV-1 in Vero cells.Glycyrrhizin can not inhibit the virus absorption and inactivate the virus.
2.Clinical research in the effects of urokinase on acute cerebral infarction in very early stage
Bin GU ; Jingsong ZHANG ; Gaonian ZHAO
Chinese Journal of Emergency Medicine 2010;19(9):957-959
Objective To study the effects of thrombolysis for the treatment of acute cerebral infarction (ACI) in early stage (within 6 hours after onset) in hospital, and to demonstrate the benefit of urokinase in the treatment of acute cerebral infarction. Method The patients with cerebral infarction treated with UK within 3hours after onset in the emergency department were enrolled as the study group, and those treated with thrombolytics in the neurological unit over the same period were taken as the control group. Results The average time from onset of ACI to starting thrombolytic therapy was 45 minutes in the study group and 80 minutes in the control group.The number of patients treated with thrombolysis within 3 hours was 39 ( 14.4% ) in the study group and 29 (10.5%) in the control group. There were significant differences in the scores of the National Institutes of Health Stroke Scale (NIHSS) after thrombolytic therapy and in Bathel index of complete or nearly complete recovery rate between two groups. The length of hospital stay was shorter in patients of the study group than that in the control group. Conclusions The thrombolytic treatment with urokinase employed to the patients in the early stage of acute cerebral infarction leads to better outcomes than that in the later stage.